Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights March 6, 2026
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis February 10, 2026
